Table 4 Summary of improvements in efficacy measures in response to etanercept by treatment group

PASI 50, % of patients (95 % CI)

72.1 (61.4, 81.2)

91.7* (83.6, 96.6)

80.2 (70.2, 88.0)

90.5 (82.1, 95.8)

PASI 75, % of patients (95 % CI)

39.5 (29.2, 50.7)

66.7* (55.5, 76.6)

62.8 (51.7, 73.0)

83.3* (73.6, 90.6)

PASI 90, % of patients (95 % CI)

14.0 (7.4, 23.1)

32.1* (22.4, 43.2)

37.2 (27.0, 48.3)

56.0* (44.7, 66.8)

Adjusted mean change from baseline in total PGA score, mean (SEM)

−1.5^† (0.1)

−2.0*^† (0.1)

−1.9^† (0.1)

−2.2*^† (0.1)

PGA clear/almost clear, % of patients (95 % CI)

36.0^† (26.0, 47.1)

56.0*^† (44.7, 66.8)

57.0^† (45.8, 67.6)

71.4^† (60.5, 80.8)

Adjusted mean % change in affected body surface area, mean (SEM)

−14.6^† (1.7)

−23.2*^† (1.7)

−21.7^† (1.5)

29.6*^† (1.5)